

The Second International Conference on

TB Vaccines for the World

TBV 2006 – 19–21 April 2006, The Austrian Industrial Association, Vienna, Austria

One in every three people on earth is believed to be infected with *Mycobacterium tuberculosis*, leading to seven to eight million cases of active tuberculosis (TB) per year and approximately three million deaths annually. This epidemic, like those of most infectious diseases, creates scientific challenges and opportunities as it raises the demand for public health solutions. The currently available weapons for fighting TB are inadequate. The ultimate goal of biomedical TB research is to lessen the public health burden of this disease by developing improved diagnostic, therapeutic, and intervention strategies. Achieving this goal requires a base of knowledge about the biology of *M. tuberculosis* and related mycobacteria, their interactions with human and animal hosts, and the nature of an effective host-protective immune response. TB researchers are applying this accumulating base of knowledge to developing rapid, easy-to-use diagnostic assays appropriate for low- as well as high-income countries, improving the current complicated therapeutic regimen, identifying potential new drugs to combat multidrug-resistant TB, and **creating more effective vaccines**.

TBV 2006, the follow-up to the successful TBV 2003 held in Montreal, will focus attention on '**Vaccine Issues**' in relation to TB worldwide. TB vaccines is a developing area of activity and TBV 2006 will allow researchers to come together to discuss the latest findings and trends associated with the research and development of TB vaccines – science, policy, strategy, delivery, economics. The TBV 2006 Scientific Advisory Panel invite the submission of late abstracts for consideration for inclusion in the TBV 2006 poster program.

Scientific Advisory Panel


Christine Sizemore (NIAID/NIH, Bethesda, USA) · Michael J Brennan (FDA, Rockville, USA)
Steve Reed (IDRI, Seattle, USA) · Peter Andersen (Statens Seruminstitut, Copenhagen, Denmark)
Doug Lowrie (NIMR, MRC, London, UK) · SHE Kaufmann (Max-Planck-Institut, Berlin, Germany)
Tom Ottenhoff (Leiden University, The Netherlands) · Alexander von Gabain (INTERCELL, Vienna, Austria)
Ian Orme (Colorado State University, USA) · Uli Fr uth (WHO, Geneva, Switzerland)
Michael Iademarco (CDC, USA) · Yasir Skeiky (Aeras Global TB Vaccine Foundation, USA)
Joe Cohen (GSK Biologicals, Rixensart, Belgium) · Leander Grode (VPM GmbH, Hannover, Germany)

Closing date for poster abstract submissions Friday 31st March 2006



Register securely on-line at: www.meetingsmanagement.com/tbv_2006

TB VACCINES
FOR THE WORLD 2006



07.30 Onwards

Registration

08.50–09.00

Welcome to Vienna & Opening Remarks

Alexander von Gabain (*Intercell AG, Vienna, Austria*)

09.00–09.15

TBV 2006 Rapporteur's Introduction

Rapporteur to be confirmed

SESSION 1:

OPENING PLENARY SESSION

Moderator: Michael Iademarco (*CDC, USA*)

09.15–09.45

'Molecular medicine and the paradigm shift in the development of vaccines against microbial diseases'

Alex von Gabain (*Intercell AG, Vienna, Austria*)

09.45–10.15

'A bolder notion of TB control'

Peter Small (*Gates Foundation, Seattle, Washington, USA*)

10.15–10.45

'Global facilitation of TB vaccine development'

Uli Früth (*WHO, Geneva, Switzerland*)

10.45–11.15

Coffee Break & Posters Set-Up

SESSION 2:

PLENARY SESSION

Moderator: Alex von Gabain (*Intercell AG, Vienna, Austria*)

11.15–11.45

'AERAS TB vaccine development'

Jerald C. Sadoff (*AERAS, Bethesda, Maryland, USA*)

11.45–12.15

'TB-VAC – EU funded tuberculosis vaccine consortium update'

Paul-Henri Lambert (*University of Geneva, Switzerland*)

12.15–12.45

'Overview of NIAID/NIH TB programs: The direction for TB vaccines'

Christine Sizemore (*NIAID/NIH, Bethesda, Maryland, USA*)

12.45–14.00

Lunch & Posters

14.00–14.30

'Background status and future plans of the TB vaccine program at GSK Biologicals'

Pascal Mettens (*GSK Biologicals, Rixensart, Belgium*)

14.30–15.00

'BIO Ventures for Global Health Business case for TB vaccines: A market perspective'

Wendy Taylor

(*BIO Ventures for Global Health, Washington DC, USA*)

SESSION 3:

STOP TB SPECIAL SESSION

Moderators: Uli Früth (*WHO, Switzerland*)

& Douglas Young (*Imperial College, London, UK*)

'Update on STOP TB initiative'

Drugs · Diagnostics · Vaccines

16.00–16.30

Tea Break & Posters

SESSION 4:

UNRESOLVED QUESTIONS/NEXT STEPS

Moderators: Uli Früth (*WHO, Switzerland*)

& Mike Brennan (*CBER/FDA, USA*)

- Upstream vaccinology
- Preclinical
- Manufacturing
- Regulation
- Developing country requirements
- Clinical

- To be confirmed

TBV 2006 OPEN FORUM/DISCUSSION

'TB Vaccines – The Way Ahead'

Panel:

Douglas Young (*Imperial College, UK – Panel Chairman*)

Uli Früth (*WHO, Switzerland*)

Mike Brennan (*CBER/FDA, USA*)

Michael Iademarco (*CDC, USA*)

Jerry Sadoff (*AERAS, USA*)

Paul-Henri Lambert (*University of Geneva, Switzerland*)

Peter Small (*Gates Foundation, USA*)

Christine Sizemore (*NIAID/NIH, USA*)

Alex von Gabain (*Intercell AG, Austria*)

Evening:

To be confirmed

SESSION 5:

TB VACCINE BACKGROUND & DEVELOPMENT

Moderator: Tom Ottenhoff (*Leiden University, The Netherlands*)

08.30–09.00

Keynote Lecture:

'Approaches to protective T cell induction in tuberculosis'
Adrian Hill (*University of Oxford, Oxford, UK*)

09.00–09.30

'Variable host-pathogen compatibility in *Mycobacterium tuberculosis*'

Sebastien Gagneux, Peter Small et al.
(*Institute for Systems Biology, Seattle, Washington, USA*)

09.30–10.00

'Immunopathology of the GP model'

Randy J. Basaraba (*Colorado State University, Fort Collins, USA*)

10.00–10.30

Coffee & Posters

10.30–10.50

'Evidence that PE-PGRS proteins of *Mycobacterium tuberculosis* may influence progression of the disease'

Mike Brennan et al. (*CBER/FDA, Bethesda, Maryland, USA*)

10.50–11.10

'An update on the NIH TB vaccine development program'

Angelo Izzo (*Colorado State University, Fort Collins, USA*)

11.10–11.30

'Evaluation of TB vaccines in the EU Framework 6 consortia using the guinea pig model – an update'

Ann Rawkins (*Health Protection Agency, Porton Down, Salisbury, UK*)

SESSION 6:

BCG ISSUES

Moderator: Doug Lowrie (*NIMR, London, UK*)

11.30–11.50

'Oral vaccination against tuberculosis'

Frank E. Aldwell, M.F. Cross, M. Lambeth and Bryce M. Buddle
(*University of Otago, Dunedin, New Zealand*)

11.50–12.10

'Administration of BCG to cattle by a combination of systemic and mucosal routes to enhance protection against bovine tuberculosis'

Bryce M. Buddle, D.N. Wedlock, M. Denis, F.E. Aldwell, H.M. Vordermeier and R.G. Hewinson
(*AgResearch, Upper Hutt, New Zealand*)

12.10–12.30

'Antigen specific changes in gene expression following vaccination with BCG or MVA85A'

Helen A. Fletcher, Kathryn T. Whelan, Clare Sander, Helen McShane and Adrian V.S. Hill (*University of Oxford, UK*)

12.30–12.50

'The pre-clinical assessment of vaccine-induced protection using different *M. tuberculosis* challenge strains'

Sheldon L. Morris et al. (*CBER, FDA, Bethesda, Maryland, USA*)

12.50–13.10

'New TB vaccine granted Orphan Drug Status'

T. Lang, R. Shah, A. Towse, C. Pritchard, M. Garan, A.V.S. Hill and H. McShane (*University of Oxford, UK*)

13.10–14.00

Lunch & Posters

SESSION 7:

TB VACCINE DESIGN & DELIVERY

Moderator: Joe Cohen (*GSK Biologicals, Rixensart, Belgium*)

14.00–14.30

'Rational vaccine design against tuberculosis: Learning from the immune response of naturally infected individuals'

Steffan Kaufmann (*MPII, Berlin, Germany*)

14.30–15.00

'Use of proteomics for TB vaccine design'

John T Belisle (*Colorado State University, Fort Collins, USA*)

15.00–15.30

'TB subunit vaccines based on fusion molecules – design and delivery'

Peter Andersen (*SSI, Copenhagen, Denmark*)

15.30–16.00

'Epitope-driven TB DNA vaccines: An immunoinformatics approach'

Annie De Groot & Julie McMurry (*Brown University/Epivax, USA*)

16.00–16.30

Coffee & Posters

SESSION 8:

NEW & NOVEL VACCINES AND TECHNOLOGIES

Moderator: Steffan Kaufmann (*MPII, Berlin, Germany*)

16.30–17.00

'Discovery of new *M. tuberculosis* antigens for vaccination'

Tom Ottenhoff
(*Leiden University Medical School, Leiden, The Netherlands*)

17.00–17.20

'New live tuberculosis vaccines based on attenuation of *Mycobacterium bovis*'

Desmond M. Collins (*AgResearch, Upper Hutt, New Zealand*)

17.20–17.40

'Development of a recombinant bacillus Calmette-Guerin vaccine candidate that has an enhanced ability to escape the endosome and overexpresses antigen 85B'

Ronggai Sun et al.
(*Aeras Global TB Vaccine Foundation, Bethesda, Maryland, USA*)

17.40–18.00

'Developing a safer and more efficacious recombinant live BCG-vaccine to stop tuberculosis'

Albrecht Laufer and Leander Grode
(*Vakzine Projekt Management GmbH, Hannover, Germany*)

Evening:

To be confirmed

SESSION 9:

CLINICAL TRIALS UPDATE – I

Moderator: Uli Früth (*WHO, Switzerland*)

08.30–09.00

'Immune correlates of protection against TB following newborn vaccination with BCG'

Willem Hanekom et al. (*University of Cape Town, South Africa*)

09.00–09.20

'Phase one trial of Modified Vaccinia Ankara 85A tuberculosis vaccine in adults in a high TB prevalence setting in South Africa'

Tony Hawkrigde, Willem Hanekom, S. Gelderbloem, H. Fletcher, B. Buthelzi, L. van der Merwe, Adrian Hill, Greg Hussey and Helen McShane (*University of Cape Town, South Africa*)

09.20–09.40

'BCG induces poor responses against Mycobacterium tuberculosis antigens encoded by the DosR regulon'

Michel Klein et al.
(*Leiden University Medical Center, Leiden, The Netherlands*)

09.40–10.00

'The DARDAR prime-boost TB vaccine trial'

C. Fordham von Reyn
(*Dartmouth Medical School, New Hampshire, USA*)

10.00–10.20

Coffee & Posters

SESSION 10:

CLINICAL TRIALS – II

Moderator: Yasir Skeiky (*Aeras, USA*)

10.20–10.40

'Boosting in latency – results of clinical trials with MVA85A in subjects latently infected with *M. tuberculosis*'

Helen McShane, Clare R. Sander, Ansar A. Pathan, Helen A. Fletcher, Geoff Pasvol and Adrian V.S. Hill
(*University of Oxford, Oxford, UK*)

10.40–11.00

'Safety and immunogenicity of the Mtb72F/AS02A tuberculosis vaccine in PPD-negative Belgian adults'

Isabel Leroux-Roels, Geert Leroux-Roels, Frédéric Clement
(*Center for Vaccinology, University Hospital; University of Ghent, Ghent, Belgium*)
Opokua Ofori-Anyinam, Philippe Moris, Els De Kock, Marie-Claude Dubois, Marie-Ange Demoitié, Pascal Mettens, Pierre Vandepapelière, Joe Cohen, W. Ripley Ballou
(*GlaxoSmithKline Biologicals, Rixensart, Belgium*)

11.00–11.20

'Issues in the definition of clinical end-points in clinical trials of new vaccines for the prevention of tuberculosis in neonates and infants'

Tony Hawkrigde, Larry Geiter and Greg Hussey (*University of Cape Town, South Africa/ AERAS, Bethesda, Maryland, USA*)

11.20–11.40

'Immune responses induced by infant BCG vaccination in Malawi and the UK'

Hazell M. Dockrell et al.
(*London School of Hygiene & Tropical Medicine, London, UK*)

SESSION 11:

DNA VACCINES

Moderator: Ian Orme (*Colorado State University, Fort Collins, USA*)

11.40–12.00

'Plasmid DNA vaccination for the study of latent TB infection in mice'

Kris Huygen et al. (*WIV-Pasteur Institute, Brussels, Belgium*)

12.00–12.20

'Novel vaccination (HVJ-liposome/HSP65 DNA+ IL-12 DNA) against tuberculosis using cynomolgus monkey'

Masaji Okada et al.
(*Kinki-Chuo Chest Medical Center, Osaka, Japan*)

12.20–12.40

'Improved humoral and cellular responses against *Mycobacterium tuberculosis* ESAT-6 antigen in mice and non-human primates following genetic immunization with a chimeric DNA vaccine encoding the ESAT-6 inserted into the Ag85A antigen'

Zhongming Li et al.
(*Shanghai H&G Biotechnology Co Inc., Shanghai, P.R. China*)

12.40–13.00

'Immune response to DNA vaccine candidates for TB'

Mahavir Singh
(*Lionex Diagnostics & Therapeutics GmbH, Braunschweig, Germany*)

13.00–14.00

Lunch & Posters

SESSION 12:

BOOSTING, ADJUVANTS, DELIVERY SYSTEMS AND IMMUNOTHERAPY

Moderator: Steve Reed (*IDRI, Seattle, Washington, USA*)

14.00–14.30

'Adjuvants and delivery systems for TB vaccines: An overview'

Steve Reed (*IDRI, Seattle, Washington, USA*)

14.30–15.00

'Development of a BCG prime- recombinant Ad35-tuberculosis booster vaccine strategy'

Yasir Skeiky et al.
(*Aeras Global TB Vaccine Foundation, Bethesda, Maryland, USA*)

15.00–15.20

'Boosting the protective efficacy of *M. bovis* BCG with synthetic Dipeptide, -D-gluamyl-l-tryptophan (SCV-07), in a murine model of pulmonary tuberculosis'

T.M. Lasco, V. Phaybouth, C.W. Tuthill and L.A. Cantarero
(*Mycos Research, Loveland, Colorado, USA*)

Provisional Conference Program – Friday 21st April 2006

15.20–15.40

'Development of vectored recombinant RNA nucleocapsids as polyvalent vehicles for delivery of TB antigens'

John Fulkerson et al.

(Aeras Global TB Vaccine Foundation, Bethesda, Maryland, USA)

15.40–16.00

Tea & Posters

16.00–16.20

'Characterization of IC31, A multipurpose adjuvant with a profile matching the need of TB vaccines'

Karen Lingnau (Intercell AG, Vienna, Austria)

16.20–16.40

'Mucosal administration of LTK63 and Ag85B–ESAT 6 protects against infection with *M. tuberculosis* and boosts BCG immunity'

Jes Dietrich, Rino Rappuoli, Claire Andersen and Peter Andersen

(Statens Serum Institute, Copenhagen, Denmark)

16.40–17.00

'Immunotherapy for TB: Pro's and con's'

Douglas B. Lowrie

(National Institute for Medical Research, Mill Hill, London, UK)

SESSION 13:

CLOSING SESSION

Moderator: Uli Früth (WHO, Geneva, Switzerland)

17.00–17.30

'Regulatory pathways for new TB vaccines'

Michael J. Brennan (CBER/FDA, Bethesda, Maryland, USA)

17.30–17.45

Rapporteur's report on TBV 2006

17.45

Closing Remarks

Dr Alexander von Gabain (Intercell AG, Vienna, Austria)

* THIS PROVISIONAL PROGRAM IS CORRECT AT TIME OF PRINTING. HOWEVER THE ORGANIZERS RESERVE THE RIGHT TO MAKE ANY ALTERATIONS THAT MAY BE REQUIRED IN THE INTERESTS OF THE CONFERENCE PROGRAM.

Provisional Conference Program – Poster Session

'Renewed interest in mucosal BCG vaccination'

Marina Gheorghiu (Pasteur Institute, Paris, France)

'Exploiting the ability of mycobacterial mammalian cell entry protein (mce1A) to alter the immune response against a subunit vaccine'

Claus Aagaard, Jes Dietrich and Peter Andersen

(Statens Serum Institute, Copenhagen, Denmark)

'Characterization of a novel adjuvant based on cationic liposomes suitable for use in TB vaccines'

Else Marie Agger, Karen Korsholm, Dennis Christensen,

Ida Rosenkrands and Peter Andersen

(Statens Serum Institute, Copenhagen, Denmark)

'Supplementing BCG with additional antigens increases the protection against *M. tuberculosis*'

Jes Dietrich and Peter Andersen

(Statens Serum Institute, Copenhagen, Denmark)

'Construction of a state-of-the-art facility for BCG manufacture that will use fermentation technology for vaccine production'

Manoj Kole et al.

(Aeras Global TB Vaccine Foundation, Bethesda, Maryland, USA)

'Post exposure vaccination in mouse models for latent *M. tuberculosis* infection'

Carina V. Lundberg, Anneline Nansen, Jes Dietrich and Peter

Anderson (Statens Serum Institute, Copenhagen, Denmark)

'Distribution of toll like receptor (TLR) 4 mutations in the Indian population and patients with pulmonary tuberculosis'

N. Najmi, S.K. Sharma and N.K. Mehra

(All India Institute of Medical Sciences, New Delhi, India)

'Immunogenic properties of virus like particles displaying BCG proteins at the surface'

M.Sh. Azaev et al. (State Research Center of Virology and

Biotechnology, Novosibirsk Region, Russia)

'CpG oligodeoxynucleotides induce two distinct signalling pathways mediated by Ca⁺⁺ – dependent phospholipase D and Ca⁺⁺ –independent phospholipase A₂ leading to mycobacterial activity in monocytes'

Maurizio Fraziano et al.

(University of Rome 'Tor Vergata', Rome, Italy)

'Short-period chemotherapy against latent TB is feasible when combined with RUTI therapeutic vaccination'

Pere-Joan Cardona

(Universitat Autònoma de Barcelona, Barcelona, Spain)

'TB determination using cocktails of antigens of 38, 16 and 6 kDa in human serum'

Lia Gardenia Partakusuma

(Persahabatan Hospital, Jakarta, Indonesia)

'In vitro and in vivo expression and invasin-like role of mammalian cell entry (Mce) proteins encoded by mce3 operon of *Mycobacterium tuberculosis*'

S. El-Shazly et al. (Kuwait University, Kuwait)

'Therapeutic DNA vaccine against TB'

Young Chul Sung

(Pohang University of science & Technology, Korea)

'TB endpoints for the DARDAR prime-boost TB vaccine trial'

Robert D. Arbeit, Lisa Adams, C. Robert Horsburgh,

C. Fordham von Reyn

(Paratek Pharmaceuticals Inc., Boston, Massachusetts, USA)

TBV 2006 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom

Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516

Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/tbv_2006

REGISTRATION

Delegates should register for TBV 2006 by completing the form provided on the back page of this brochure. The completed Conference Registration Form plus payment (payment in UK £ Pounds Sterling) should be sent to the TBV 2006 Conference Manager – Caroline Sumner at Meetings Management. The TBV 2006 Conference Registration Desk will be open from 7.30am on Wednesday 19th April 2006. **Delegates can also register securely on-line at: www.meetingsmanagement.com/tbv_2006**

VENUE & ACCOMMODATION

The organizers have negotiated special discounted accommodation rates for TBV 2006 delegates at the **Radisson SAS Palais Hotel** and the **Sofitel Vienna Hotel**. Please use the Accommodation Booking Form provided in this brochure to qualify for the special rates.

The venue for the TBV 2006 conference is: **Federation of Austrian Industry**, IndustrieHaus-Verein, Schwarzenbergplatz 4, A-1030 Vienna, Austria.

Poster Papers

Late poster paper submissions are invited and prospective authors should submit a one page abstract of their poster(s) to the Conference organizers (Meetings Management) for consideration. Please send your poster for the attention of John Herriot (E-mail: jherriot@meetingsmgmt.u-net.com) at Meetings Management. **Late poster abstracts should be submitted by Friday 31st March 2006.**

PUBLICATION

A CD ROM of final programme and abstracts of all presentations, oral and poster, will be distributed to delegates when they register at the conference.

TABLE TOP EXHIBITION

Table Top Exhibition space is available at the meeting. Exhibitors can showcase their products or services by reserving a table top exhibit. The exhibit area will be located adjacent to the main conference area where all refreshments breaks will be taken to ensure maximum traffic of conference delegates. If you are registering for the conference, you can reserve a table for £995. If you do not wish to attend the conference sessions, you can reserve a table for £1995 (includes admission to all meals/receptions by one company representative).

PLEASE NOTE: If you wish to have additional representatives on your table top exhibit there will be an additional charge for catering levied per head. Please contact the Conference Manager for this additional price.

Please make your bookings and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Table Top Exhibition facilities at TBV 2006 should be directed to John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com)

DELEGATE PACK INSERT SERVICE

Company literature/brochures/conference brochures may be distributed to delegates as part of the documentation issued on arrival/registration. One insertion in the TBV 2006 delegate pack is priced at £425. Please make your booking and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Delegate Pack Insertion services at TBV 2006 should be directed to John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com)

PLEASE NOTE: Literature for distribution to TBV 2006 delegates is subject to approval by the conference organizers.

INSURANCE & CANCELLATION

The organizers cannot be held responsible for any personal accident or damage to their private property of participants at TBV 2006. The organizers strongly urge participants to ensure they have adequate travel and personal insurance cover before they depart for the conference. The organizers cannot be held liable for any costs incurred should the conference be cancelled for any reason. Maximum notice of cancellation will be given by the organizers to all pre-registered delegates.

PROGRAM

The TBV 2006 Scientific Advisory Panel and the TBV 2006 Conference Organizers reserve the right to alter any part of the published conference program if this is necessitated by any circumstances outside their control. All efforts will be made to keep any such changes to a minimum. The program published in the brochure was correct at the time of going to press.

CANNOT ATTEND?

If you and your colleagues are unable to attend the conference, the conference materials (CD ROM of abstracts, speaker handouts, late abstracts, attendee list, pack materials and literature) are available for purchase. While not intended as a substitute for actual attendance, these materials would at least provide a documentary record of the event and allow you to keep you or your organization's library up to date. The cost of providing this non-attendee package is £365 (including postage and packing). To order this package from Meetings Management please use the relevant section in the Delegates Registration Form on the back page of this brochure.

ANY QUESTIONS?

For further information and assistance, please contact: Caroline Sumner TBV 2006 Conference Manager (details below).

TBV 2006 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom
Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/tbv_2006

Sponsors

The TBV 2006 Scientific Advisory Panel and the organizers would like to acknowledge the support of the following sponsors:



Poster Papers – Late Submissions

Additional poster paper submissions are welcomed and prospective authors are invited to submit one page abstracts to the TBV 2006 Conference Organizers (Meetings Management) for consideration.

Please e-mail your poster abstracts to: John Herriot (jherriot@meetingsmgmt.u-net.com) or by fax on +44 (0)1483 428516

LATE POSTER ABSTRACTS SHOULD BE SUBMITTED BY FRIDAY 31ST MARCH 2006

Table Top Exhibition

Table top exhibition space is available at TBV 2006. Exhibitors can showcase their products/literature or services by reserving a table top exhibit (or exhibit their own display boards) during the conference.

To reserve your table top/display space at TBV 2006 please use the relevant section in the Delegate Registration Form at the back of this brochure.

Hotel Accommodation Form for TBV 2006

To make your hotel reservation please fax or mail the completed form to the relevant hotel (this form must be used to qualify for the special conference rate).

Important: Accommodation reservations are the sole responsibility of the delegate. Rooms have been reserved specifically for TBV 2006, at the quoted discounted rates and are available 3 days pre and post conference. To benefit from the special accommodation rates please make all the necessary reservations before the cut off date of 19th March 2006. After this date accommodation will be subject to availability. If your travel plans should change after this form has been submitted, please notify your chosen hotel immediately.

RADISSON SAS PALAIS HOTEL (5*)

Reservations Department, Parkring 16, 1010 Vienna, Austria
Telephone: +43-(0) 1-515 17-0 Fax: +43-(0) 1-515 17-3510
Web: www.radissonsas.com
Email: reservations.vienna@radissonsas.com

Classic Single €210 Classic Double/Twin €210

Rates are per night and are inclusive of taxes, service and breakfast and must be guaranteed by credit card or paid in full at the time of booking. Up to 14 days before arrival the reservation can be cancelled free of charge. In the event of cancellation less than 14 days prior to arrival the total amount applicable for your entire stay will be chargeable. This also applies to no shows.

SOFITEL VIENNA HOTEL (4*)

Reservations Department, Am Heumarkt 35-37, 1030 Vienna, Austria
Telephone: +43-(0) 1-716 16-812 Fax: +43-(0) 1-716 16-844
Web: www.sofitel.com Email: h1276@accor.com

Single €180 Double/Twin €180

Rates are per night and are inclusive of taxes, service and breakfast and must be guaranteed by credit card or paid in full at the time of booking.

Family Name Title

First Name

Job Title

Organization

Address

Post/Zip Code Country

Tel Fax

E-mail

Passport No Expiry Date

Place of Issue Date of Issue

Arrival Date Flight ETA

Departure Date Flight ETA

CREDIT CARD GUARANTEE

To: Amex VISA MasterCard

Card No.

Expiry Date

Cardholders Name

Cardholders Signature

FOR HOTEL USE ONLY

Booking is confirmed/not confirmed

Acknowledged by Date

Remarks

TBV 2006 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom

Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516

Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/tbv_2006

